|
Evaluation of the Cytotoxic Effects of Diclofenac on Pancreatic Cancer Cells (PANC-1) Compared to Non-Cancerous Human Embryonic Kidney Cells (HEK293)
|
Yasam Aliyan    , Rahim Ahmadi , Tahereh Ghaderi Barmi , Sajedeh Asrar , Nooshin Amini * |
| Member Global Research, Education, and Event Network (GREEN), Iran & Member Global Research, Education, and Event Network (GREEN), Iran , amini.n.2486@gmail.com |
|
|
Abstract: (4 Views) |
Background and Aim: Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), is one of the deadliest gastrointestinal malignancies with a poor prognosis. This study aimed to investigate the cytotoxic effects of diclofenac on pancreatic cancer cells (PANC-1) and to assess its potential as an adjuvant drug in treating this cancer.
Materials and Methods: This in vitro study was conducted on the PANC-1 and HEK293 cell lines. Cells were cultured in standard DMEM medium and treated with various concentrations of diclofenac. Cell viability was evaluated using the MTT assay after 48 hours of treatment. The IC₅₀ value was calculated by analyzing the dose-response curve using GraphPad Prism software. Data were analyzed using ANOVA and Tukey’s post-hoc test.
Results: Diclofenac at concentrations ranging from 31.25 to 500 µg/mL caused a significant decrease in cell viability in both PANC-1 and HEK293 cell lines (P < 0.001). The IC₅₀ value of the drug was found to be 96 µg/mL in the PANC-1 cell line and 107 µg/mL in the HEK293 cell line, indicating a considerable cytotoxic effect of the drug on PANC-1 cells.
Conclusion: Diclofenac exhibits potential cytotoxic and anticancer effects on pancreatic cancer cells and may serve as a promising adjuvant option in developing novel therapeutic strategies for this cancer. However, further preclinical and clinical studies are warranted to fully evaluate its efficacy and safety.
|
|
| Keywords: Pancreatic cancer, Diclofenac, Cytotoxicity, PANC-1 cell line, HEK293 cell line |
|
|
|
Type of Study: Research |
Subject:
General
Received: 2025/08/10 | Revised: 2025/09/30 | Accepted: 2025/09/14
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
_-_Copy.png)
.png){kind=logo}
